| |
Idenix Announces 13 Abstracts on Hepatitis B and C Accepted for the 2006 Annual Meeting of the European Association for the Study of the Liver (EASL)
|
| |
| |
Source: Idenix Pharmaceuticals
Idenix Pharmaceuticals announced this week that 13 of its submitted abstracts on therapy for chronic hepatitis B and hepatitis C have been accepted for presentation at the 41st annual meeting of the European Association for the Study of the Liver (EASL), to be held in Vienna, Austria, April 26-30, 2006.
Telbivudine is an investigational compound for the treatment of hepatitis B. Idenix is currently evaluating telbivudine in an ongoing two-year international phase III clinical trial referred to as the GLOBE study. The GLOBE study, in which 1,367 patients are enrolled, is comparing 600 mg dose of telbivudine orally administered once a day to treatment once a day with 100 mg of lamivudine. The most frequently reported adverse events in the GLOBE study were upper respiratory tract infection, nasopharyngitis, fatigue and headache. Creatine kinase (CK) elevations, not requiring treatment modification, were more common among patients treated with telbivudine compared to lamivudine.
EASL Abstracts on Telbivudine
Idenix is developing its hepatitis B product candidates in collaboration with Novartis Pharma AG under a license granted by Idenix and a development and commercialization arrangement established in May 2003.
Stefan Zeuzem, Professor of Medicine at Saarland University, in Homburg, Germany, will present "Optimal Virologic and Clinical Efficacy at One Year is Associated with Maximal Early HBV Suppression in Nucleoside-Treated Hepatitis B Patients" in a meeting session on Friday, April 28 at 5:15 p.m. CET.
Henry Chan, Associate Professor of Medicine at the Chinese University of Hong Kong, will present "A Randomized Trial of Telbivudine (LdT) vs. Adefovir for HBeAg-Positive Chronic Hepatitis B: Results of the Primary Week 24 Analysis" in a meeting session on Friday, April 28 at 5:30 p.m. CET.
Satawat Thongsawat, Professor of Medicine at Chiang Mai University in Thailand, will present "Telbivudine Displays Consistent Antiviral Efficacy Across Patient Subgroups for the Treatment of Chronic Hepatitis B: Results from the GLOBE Study" in a meeting session on Sunday, April 30 at 1:15 p.m. CET.
Nikolai Naoumov, Consultant Physician at the Institute of Hepatology, University College London, England, will present "Effect of Core Promoter/Precore Mutation Pattern and Early Virologic Response on Efficacy Outcomes with Telbivudine in HBeAg-negative Chronic Hepatitis B" in the poster session beginning on Thursday April 27, 2006 at 7:00 p.m. CET.
Edward Gane, Associate Professor of Gastroenterology and Hepatology at Middlemore Hospital in Auckland, New Zealand, will present "Phase III Comparison of Telbivudine vs. Lamivudine in HBeAg-Positive Patients with Chronic Hepatitis B: Efficacy, Safety, and Predictors of Response at 1 Year" in the poster session beginning on Thursday, April 27, 2006 at 7:00 p.m. CET.
Xiao-Jian Zhou will present "Absence of Pharmacokinetic Drug-Drug Interaction Between Telbivudine and Peginterferon alfa-2a or Cyclosporine in Healthy Subjects" in the poster session beginning on Thursday, April 27, 2006 at 7:00 p.m. CET.
David Standring, Idenix's Senior Vice President, Biology, will present "HBV Resistance Determination from the Telbivudine GLOBE Registration Trial" in the poster session beginning on Thursday, April 27, 2006 at 7:00 p.m. CET.
Edward Bridges, Idenix's Vice President, Preclinical Pharmacology and Toxicology, will present "Telbivudine Preclinical Safety Studies Suggest Minimal Risk of Chronic Toxicity, Reproductive Toxicity or Carcinogenicity" in the poster session beginning on Thursday, April 27, 2006 at 7:00 p.m. CET.
|
|
| |
| |
|
|
|
